Shortwave is pleased to announce the strategic appointment to the board of Mr Keith Coughlan, a fundraising and that it is extending its area of operational focus into the resources sector.
Read more: https://t.co/AcznLgkboQ #PSY#CriticalMetals
During a pivotal 2025 Shortwave Life Sciences (AQSE:PSY) has transitioned into a biopharmaceutical company focused on novel drug combinations and delivery methods designed to treat patients suffering from mental health disorders.
Why now?
Mental health crisis rising. Regulators opening doors to new therapies. Digital assets gaining institutional adoption.
Shortwave stands at the inflection point — biotech + blockchain, the next frontier.
#PSY
Shortwave uniquely positioned at the convergence of two high-growth markets.
🧠 $180B CNS disorders by 2030
💰 Digital Assets $4T market cap +245% last two years
Learn more: https://t.co/lceDPt4Wzd
#PSY